Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OZPWU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EphA2-targeted mAb ADC B 22 (DAR2)
|
|||||
| Synonyms |
EphA2-targeted-mAb-ADC-B-22-(DAR2)
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Hodgkin lymphoma [ICD11:2B30]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
EphA2-targeted mAb ADC B 22 (DAR2) linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.